Prognostic significance of $^{18}$FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis

Qian Xia¹, Jianjun Liu¹, Cheng Wu², Shaoli Song¹, Linjun Tong¹, Gang Huang¹*, Yuanbo Feng³, Yansheng Jiang³, Yewei Liu³, Ting Yin³ and Yicheng Ni³*

Abstract

Background: The role of 18-fluorodeoxyglucose positron emission tomography CT ($^{18}$FDG PET/CT), as a prognostic factor for survival in colorectal cancer patients with liver metastases, is still controversial. We sought to perform a meta-analysis of the literature to address this issue.

Methods: A systematic literature search was performed to identify the studies that associated $^{18}$FDG PET/CT to clinical survival outcomes of patients with liver metastases. Methodological qualities of the included studies were also assessed. The summarized hazard ratio (HR) was estimated by using fixed- or random-effect model according to heterogeneity between trails.

Results: By analyzing a total of 867 patients from 15 studies, we found that PET/CT for metabolic response to the therapy was capable of predicting event-free survival (EFS) and overall survival (OS) with statistical significance, and the HR was 0.45 (95 % confidence interval [CI], 0.26–0.78) and 0.36 (95 % CI, 0.18–0.71), respectively. Furthermore, pre-treatment $^{18}$FDG PET/CT with high standardized uptake value (SUV) was also significantly associated with poorer OS HR, 1.24; (95 % CI, 1.06–1.45). However, we did not find a statistically significant effect of post-treatment SUV for predicting OS HR, 1.68; (95 % CI, 0.63–4.52).

Conclusions: The present meta-analysis confirms that $^{18}$FDG PET/CT is a useful tool to help predict survival outcomes in patients with liver metastases.

Keywords: SUV, Meta-analysis, Liver metastases, PET/CT, Prognosis

Background

The liver is the most common site for hematogenous spreading of metastatic neoplasms. Metastases can result from a wide variety of malignancies, with the most widely known being from colorectal origins. Previous study indicated that liver metastases were detected in 40–50 % of nearly one million patients who were diagnosed with colorectal cancer worldwide each year [1]. In the past, only 10 % of such patients with liver metastases were eligible to surgery. New chemotherapy regimens and improvement in surgical techniques have now allowed surgically treating patients with liver metastases in more advanced stages of illness. Radioembolization using yttrium-90 ($^{90}$Y) resin, also known as selective internal radiation therapy (SIRT), is a palliative treatment, which reduces the liver tumor mass and might eventually permit surgical resection. However, treatment outcomes of liver metastases remain heterogeneous. Therefore, finding reliable prognostic indicators or biomarkers, especially with those non-invasive imaging methods, would be very helpful in the management of patients with liver metastases, which has aroused great research and clinical interests.

Over the recent decades, 18-fluorodeoxyglucose positron emission tomography ($^{18}$FDG PET/CT) has played an increasing role in clinical management of liver metastases. Unlike traditional anatomical imaging modalities,
PET/CT can provide not only morphological but also functional information in a single session [2]. In particular, $^{18}$FDG as a glucose analogue has become the most popular PET tracer to visualize abnormal glucose metabolism in oncology. Because enhanced glucose metabolism is related to the aggressiveness of cancer cells, $^{18}$FDG PET/CT yielded superior results in monitoring therapy response and predicting survival in patients with a range of malignant tumors [3–7]. The changes in tumor size and/or tumor number, which reflect the number of neoplastic cells, can be used as a radiological or anatomic indicator of the tumor response [8]. Nowadays, $^{18}$F-FDG PET/CT has been used frequently for the assessment of therapeutic responses. It is particularly preferred over anatomical imaging in patients receiving noncytotoxic therapy as it returns to normal much more quickly [9]. Although the tumoral $^{18}$F-FDG uptake tends to vary for a number of reasons, there is a direct correlation between $^{18}$F-FDG uptake and viable tumor cells. In addition, previous research [10] found a significant agreement between anatomic and metabolic criteria. Recent studies have correlated high $^{18}$FDG uptake in tumors with poorer patient survival in lung, breast, head and neck, and esophageal cancers [11–13]. Furthermore, pretreatment tumoral $^{18}$FDG uptake has been shown to represent an independent prognostic factor in patients with liver metastases undergoing whatever primary treatment modalities [14, 15]. At present, a frequently used quantitative method in PET is the standardized uptake value (SUV). Compared with various other quantitative approaches, clinical appeal of SUV lies in its simplicity and high reproducibility, thanks to implemented modern computer software. It plays an important role in the evaluation of patient responses to therapies. Practitioners rely heavily on changes in SUVs over time, in the absence of clear improvement or progression of disease by detection of previous lesions or new lesions, respectively, to decide whether to continue or switch therapies. Thus, not surprisingly, an overwhelming volume of SUV data has accrued in PET-related oncologic literature during recent decade. However, the results about the prognostic value of SUV from $^{18}$FDG-PET/CT in colorectal cancer patients with liver metastases remain uncertain due to small sample size, various inclusion criteria, and different data analysis strategies. Therefore, through a current literature review, for the first time to our knowledge, we have performed a meta-analysis to assess the prognostic value of SUV from $^{18}$FDG-PET/CT for the survival of patients with liver metastases.

Methods
Search strategy
We searched PUBMED, EMBASE, and MEDLINE for articles published between January 2000 and March 2015 to identify the studies evaluating the prognostic value of $^{18}$FDG PET/CT in long-term survival prediction for patients with liver metastases. We used following search terms: liver metastases, $^{18}$FDG PET/CT, prognosis, and survival. If overlapping patient cohorts were used between several studies, we only retained the latest or the largest study to avoid duplication of information. When key information for meta-analysis was missing, we contacted the researchers of selected studies for supplying additional data. Only articles published in English were included. As this analysis is merely a retrospective literature review, neither Institutional Review Board approval nor informed consent was required by national and regional laws.

Inclusion criteria
The eligibility of abstracts and full texts were assessed by three reviewers independently. Disagreements were resolved by discussion. Studies on which agreement could not be accessed were all included for full text screening. According to a previous report [16], the relevant studies were manually selected carefully based on the following criteria: 1) include more than 10 colorectal cancer patients with liver metastases who underwent treatments; 2) use once $^{18}$FDG PET/CT scan (pretreatment or post-treatment) or twice $^{18}$FDG PET/CT scans (pretreatment and post-treatment) to predict the survival of patients, where PET/CT was evaluated alone or in comparison to other tests; 3) report prognostic outcomes such as overall survival (OS), progression-free survival (PFS), disease-free survival (DFS) and relapse-free survival (RFS), and compare the outcomes between positive and negative results of $^{18}$FDG PET/CT; and 4) contain extractable survival data of hazard ratio. However, reviews and other editorial materials were excluded and the studies only focusing on the performance of $^{18}$FDG PET/CT in diagnosis, staging, and monitoring recurrence or metastasis were also excluded. In addition, reports concerning patients with suspected or diagnosed recurrent disease were not adopted.

Qualitative assessment
Three investigators reviewed all the publications to assess their methodological quality, determine their eligibility for inclusion in the quantitative meta-analysis and extract the most important information determining the clinical and $^{18}$FDG PET/CT characteristics. As shown in Table 1, a methodological quality scale has been adapted from a previous study [17] for the purpose of this study using the variables available from the publications. The clinical report and $^{18}$FDG PET/CT report were scored on 30 and 18 points respectively. A value between 0 and 2 was attributed to each item. When items were not applicable to a particular study, they were ruled out. The
scores were expressed in percentage of the maximal theoretical value that could be obtained.

Data extraction and analyses
From those selected articles, two independent reviewers extracted the data that include the first author, publication year, study design, sample size, PET/CT timing, type of treatment received and end points for evaluating the prognostic performance. Specifically, PFS or RFS were merged as one outcome newly defined as event-free survival (EFS), which was measured from the date of therapy initiation to the date of recurrence or progression. We took overall survival (OS) as another outcome index. Patients underwent once PET/CT scan (pre- or post-treatment) were divided into high SUV and low SUV groups according to SUV cutoff values or visual observation. In patients underwent twice PET/CT scans (pre-treatment and post-treatment), the difference between baseline and follow-up SUV values (ΔSUV) was used to differentiate responding from nonresponding based on the definition in each individual study. Survival data from all studies were analyzed by means of the Kaplan-Meier curves, unless hazard ratios (HRs) were reported and compared to calculate HR and 95 % confidence intervals (CI) as previously described by Parmar et al. [18] and Tierney et al. [19]. These effects were combined to compare the low SUV or metabolic responding and high SUV or metabolic nonresponding arms for the overall effect. If the numerator and denominator appeared opposite in an article, we chose to use ln(HR) and the generic inverse variance method in software Review Manager 5.3.0 to get a result. HR < 1 indicated the survival benefit from a metabolic responding low SUV, whereas HR > 1 denoted an increased risk of metabolic nonresponding progression and death. It is considered statistically significant when a P-value is less than 0.05. Statistical heterogeneity was measured using the chi-square Q test, while P < 0.10 was considered to represent

| Assessment parameter                                      | Scale | |
|-----------------------------------------------------------|-------|---|
| Clinical reports Prognostic factors                       | Age   | 0 2 |
|                                                           | Gender| 0 2 |
|                                                           | Performance status | 0 2 |
| Tumor characteristics                                    | Location of primary tumor | 0 2 |
|                                                           | Number of metastatic sites | 0 2 |
|                                                           | Size of hepatic metastasis | 0 2 |
|                                                           | Differentiation grade | 0 2 |
| Description of the results of survival analysis            | Number of patients | 0 2 |
|                                                           | Number of deaths | 0 2 |
|                                                           | Follow-up duration | 0 2 |
|                                                           | Number of patients lost to follow-up | 0 2 |
|                                                           | Univariate and multivariate analyses | 0 2 |
|                                                           | Description of statistical tests | 0 2 |
|                                                           | Survival definition | 0 2 |
|                                                           | SUV cutoff definition or response definition | 0 2 |

| Subscores | |
|----------------------|---|
| PET/CT reports Patients’ Characteristics                  | Weight | 0 2 |
|                                                           | Glycaemia | 0 2 |
| 18FDG PET acquisition protocol characteristics             | Injected dose of 18FDG | 0 2 |
|                                                           | Delay between injection | 0 2 |
|                                                           | Data acquisition | 0 2 |
|                                                           | Fasting duration | 0 2 |
| Technical Parameters                                         | SUV formula | 0 2 |
|                                                           | Type of PET/CT engine | 0 2 |
|                                                           | Type of SUV attenuation and reconstruction parameters | 0 2 |

| Subscores | |

Total scores
significant statistical heterogeneity, and expressed by the $I^2$ statistic, as described by Higgins et al. [20]. Funnel plot was performed for testing publication bias. Survival rates on the graphical survival curves were read by software Engauge Digitizer version 4.1. (Trolltech, Oslo, Norway). HRs and their variations were calculated by Review Manager 5.3.0 (The Nordic Cochrane Centre, Copenhagen, Denmark).

Results
Study inclusion and characteristics analyses
An internet-based electronic search resulted in 196 potentially eligible articles from all databases. Among them, 147 articles were excluded based on their abstracts, including 3 non-English articles, 4 case reports, 7 reviews, and 133 articles that were irrelevant to prognostic performance of $^{18}$FDG PET/CT in patients with liver metastases. The remaining 49 full-text articles were further analyzed for eligibility. Of these studies 33 were excluded because the log HR and its variance could not be calculated and one article was only excluded for inaccessible full text. Finally, a total of 15 studies were determined to be qualified for the actual meta-analysis. Figure 1 illustrates the inclusion process and reasons for exclusion. Finally, a total of 867 patients from these 15 studies were analyzed, and the characteristics of selected studies are described in Table 2. The main SUV and ΔSUV characteristics reported in the publication are presented in Tables 3 and 4.

Qualitative assessment
Overall, the publications’ quality score ranged from 50 to 83.33 %, with a median score of 68.33 % (Table 2). If necessary, we attempted to contact the authors to gain missing details of the methodological quality.

Meta-analyses
Predictive value of ΔSUV for EFS
A total of 7 studies focused on predictive value of ΔSUV for EFS, 5 studies showed that there were significant differences between responding and nonresponding groups for EFS prognosis, 1 study did not indicate this outcome. Figure 2 shows the results of meta-analysis of the 7 studies containing 247 patients comparing EFS in the responding group with that in the non-responding group (p < 0.0001). With a summarized HR less than 1, it suggests a survival advantage for the responding group. We find heterogeneity between the studies ($I^2 = 0 \%, p = 0.84$). In pooled analysis, EFS was significantly better in responding group, 0.45 (95 % CI, 0.26–0.78) by random model.

Predictive value of ΔSUV for OS
Seven studies covering 334 patients were analyzed in this comparison. With $I^2 = 82 \%$, the heterogeneity could not be ignored between the studies. Thus, we chose random model to calculate the summarized HR, 0.36 (95 % CI, 0.18–0.71), suggesting that the OS was significantly better with responding group (p = 0.004) as revealed in Fig. 3.

Predictive value of pretreatment SUV for OS
As displayed in Fig. 4, six studies involving 509 patients were evaluated in this comparison. The OS disadvantage for high SUV PET/CT images over low SUV ones was statistically significant (p = 0.008), the test for heterogeneity was no statistically significant ($I^2 = 46 \%, p = 0.10$). By fixed-effects model with a summarized HR, 1.24
(95%CI, 1.06–1.45), it suggests that high SUV PET/CT results were associated with poor OS.

**Predictive value of post-treatment SUV for OS**

Three other studies including 55 patients were assessed to estimate the prognostic value for predicting OS by post-treatment PET/CT. The results are demonstrated in Fig. 5, indicating that there was no statistically significant difference in OS between high SUV PET/CT group and low SUV PET/CT group for OS, HR, 1.68; (95%CI, 0.63–4.52), P = 0.30. There was significant heterogeneity between researches ($I^2 = 67 \%$; $P = 0.08$).

**Discussion**

Recently, the degree of tumor uptake of $^{18}$FDG on PET as assessed by the SUV was shown to be an independent

### Table 2 Principal characteristics of the 15 studies included in the meta-analysis

| Study                  | Publication year | Number of patients | Study design | PET/CT timing | Type of treatment | End points$^a$ | Methodology score (%) |
|------------------------|------------------|--------------------|-------------|---------------|-------------------|---------------|-----------------------|
| de Geus-Oei L F et al. | 2006             | 152                | Retrospective | Pretreatment   | Resection or Chemotherapy | OS           | 83.33 %               |
| Small RM et al. [21]   | 2009             | 54                 | retrospective | Pretreatment and posttreatment | Chemotherapy | OS EFS(PFS)  | 50.00 %               |
| Hendlisz A et al.      | 2011             | 41                 | Prospective  | Pretreatment and posttreatment | Chemotherapy | OS EFS(PFS)  | 70.83 %               |
| Muralidharan V et al.  | 2012             | 30                 | retrospective | Pretreatment   | Resection        | OS EFS(RFS)  | 75.00 %               |
| De Bruyne S et al. [22]| 2012             | 19                 | Retrospective | Pretreatment and posttreatment | Chemotherapy and bevacizumab | EFS(PFS)    | 75.00 %               |
| Lastoria S et al.      | 2013             | 33                 | Retrospective | Pretreatment and posttreatment | Chemotherapy and Bevacizumab | EFS(PFS) OS  | 66.67 %               |
| Mertens J et al. [23]  | 2013             | 18                 | Prospective  | Pretreatment and posttreatment | Chemotherapy and Bevacizumab | OS           | 75.00 %               |
| Zerizer I et al.       | 2013             | 25                 | Retrospective | Pretreatment and posttreatment | $^{90}$Y radioembolization | EFS(PFS)    | 70.83 %               |
| Fendler W P et al.     | 2013             | 80                 | Retrospective | Pretreatment and posttreatment | $^{90}$Y radioembolization | OS           | 62.50 %               |
| Jones C et al.         | 2014             | 79                 | retrospective | Pretreatment   | Resection       | OS           | 54.17 %               |
| Lee HS et al. [24]     | 2014             | 120                | Retrospectively | Pretreatment   | Resection       | OS EFS(RFS)  | 83.33 %               |
| Lau LF et al.          | 2014             | 37                 | retrospective | Pretreatment and posttreatment | Chemotherapy | OS EFS(RFS)  | 58.33 %               |
| Riedl CC et al. [25]   | 2007             | 90                 | retrospective | Pretreatment   | Resection       | OS           | 54.17 %               |
| Correa-Gallego C et al.| 2015             | 38                 | Prospective  | Pretreatment and posttreatment | Chemotherapy and bevacizumab | EFS(PFS)    | 83.33 %               |
| Sabet A et al.         | 2015             | 51                 | retrospective | Pretreatment and posttreatment | $^{90}$Y radioembolization | OS           | 70.83 %               |

$^a$end points: time elapsed between treatment initiation and disease progression or death

### Table 3 Main SUV (pretreatment or posttreatment) characteristics extracted from the 9 articles used for meta-analysis

| Study                  | Type of SUV | Correction of SUV | Threshold definition | SUV threshold |
|------------------------|-------------|-------------------|----------------------|---------------|
| de Geus-Oei L F et al. | preSUVmean  | Body weight       | Median               | >4.26         |
| Muralidharan V et al.  | preSUVmean  | Body weight       | Best cut-off         | >10           |
| De Bruyne S et al.     | postSUVmax  | Body weight       | Median               | >2.85         |
| Mertens J et al.       | postSUVmax  | Body weight       | Median               | 2.85          |
| Claire Jones.et al.    | PreSUVmean  | Body weight       | Arbitrary            | >7.0          |
| Lee HS et al.          | Pre$n$SUVpeak| Body weight       | Median               | >5.0          |
| Lau LF et al.          | postSUVmax  | Body weight       | Previous report      | >10           |
| Riedl CC et al.        | preSUVmax   | Body weight       | Best cut-off         | >10           |
| Correa-Gallego C et al.| preSUVmax   | Body weight       | Median               | >10           |

$n$SUVpeak: normalized SUVpeak
prognostic factor in liver metastases [26, 27], but some studies have not found a significant association between SUV and prognosis [28–30]. Apparently, there have been controversial results. Therefore, we have elaborated this meta-analysis to evaluate the prognostic value of \(^{18}\)FDG PET-CT for liver metastases.

This meta-analysis has provided two meaningful findings regarding the use of \(^{18}\)FDG-PET for predicting survival of patients with liver metastases. First, some studies do have addressed the predictive value of patients with metabolically nonresponding liver metastases after treatment for OS and EFS. Through our quantitative analysis, the risk of death in nonresponding group was 2.5 times as high as the responding group in OS and 2.632 times in EFS. We assumed that these tumors are more aggressive or invasive with hyperactive metabolism as displayed in \(^{18}\)FDG PET/CT images. Although a range of factors has been associated with \(^{18}\)FDG uptake, there appears to be a rather strong relationship between \(^{18}\)FDG uptake and cancer cell mass in a number of studies [31, 32]. The metabolic response, which might be the strongest marker of prognosis, was measured in tumors that were ultimately resected. It appeared that the value of metabolic response was not just for the evaluation of the visible hepatic lesions but also for serving as an indicator for the sensitivity to chemotherapy among potentially undetectable micro-metastases. Current imaging technologies have limitations in resolution, with PET systems being able to detect tumors as small as 0.3–0.7 cm. This corresponds to a minimum detectable tumor size with about \(10^8–10^9\) cells [33]. Consequently, it is reasonable that declined tumor SUV would be seen with a loss of viable cancer cells, and increased tumor glucose use and volume of tumor cells would be expected in progressive tumors. The evaluation of metabolic response before planned resection of liver metastases includes the strengths of being noninvasive, repeatable, quantifiable and discriminative towards clinical outcomes. At present, \(^{18}\)FDG PET/CT appears to be the best prognostic tool available for the oncologists in the field of hepatobiliary surgery [34].

Secondly, our meta-analyses on the prognostic value of pre-treatment SUV measured on metastatic sites also showed that high SUV was an independent prognostic factor for poorer OS. By quantitative analyses, the risk of death in high SUV group was 1.12 times the low SUV.

### Table 4

Main \(\Delta\)SUV characteristics extracted from the 8 articles used for meta-analysis

| Study          | Type of SUV | Correction of SUV | Threshold definition            | SUV threshold |
|----------------|-------------|-------------------|---------------------------------|---------------|
| Small RM et al.| \(\Delta\)SUV | Body weight       | Visual observation, unclear     |               |
| Hendliz A et al.| \(\Delta\)SUVmax | Body weight | EORTC metabolic decrease > 25% |               |
| De Bruyne S et al.| \(\Delta\)SUVmax | Body weight | EORTC metabolic decrease > 25% |               |
| Lastoria S et al.| \(\Delta\)SUVmax | Body weight | Median metabolic decrease > 50% |               |
| Zerizer I et al.| \(\Delta\)SUVmax | Body weight | Best cut-off metabolic decrease > 20% |               |
| Fendler W P et al.| \(\Delta\)SUVmax | Body weight | PERCIST metabolic decrease > 30% |               |
| Correa-Gallego C et al.| \(\Delta\)SUVmax | Body weight | WHO metabolic decrease > 25% |               |
| Sabet A et al.| \(\Delta\)SUV | Body weight | Best cut-off metabolic decrease > 50% |               |

\(\Delta\)SUV : difference between baseline and follow-up SUVmax values

EORTC: The criteria of the European Organisation for Research and Treatment of Cancer

PERCIST: PET Response Criteria in Solid Tumors

WHO: WHO Criteria

Fig. 2 Forest plot of 7 included studies in \(\Delta\)SUV for EFS. Pooled effect (HR) and heterogeneity test of a metabolic responding on EFS in patients with liver metastases (EFS: event-free survival; HR: hazard ratio)
group in OS (95% CI 0.01–0.25, P = 0.04), no matter whether patients subsequently underwent curative surgery or chemotherapy. This is most likely due to the fact that high SUV tumors are more aggressive and metastatic, thus leading to relatively worse prognosis. One-unit increase in SUV could correspond to a significant increase of 17% in the risk of death [35]. Thus, our data suggest that intense glucose metabolism in liver metastases is a negative marker of prognosis. However, there existed large discrepancies among the cutoff values to distinguish high SUV from low SUV PET results (thresholds varying from 2.85 to 20). Higashi et al. [36] and Vansteenkiste et al. [37] indicated that dichotomization with a wide-ranging of SUVs gave significantly discriminative log-rank probability values. This suggests that the relationship between SUV and prognosis could be a gradual one rather than based on a threshold. The wide range of SUV thresholds seen in these articles can be due to several factors such as institution-based technical variations, the heterogeneity of the patient cohorts analyzed and the variance in the PET scanners and acquisition protocols used.

As subjective criteria were used in some studies (Table 3), despite such variability, we were able to show that the SUV was indeed correlated with patient survival. In our study, we summarized an HR from individual articles based on the SUV threshold used in each particular study, which helped to cancel the threshold factor to a certain extent. By doing so, we could demonstrate that the SUV was surely worth considering as a prognostic factor in patients with liver metastases. In addition, only three studies dealing with the predictive value of post-treatment SUV for OS were included. One of these two studies with a total of 18 patients indicated significant OS benefit of low SUV after treatment, but another study with 37 patients showed an opposite conclusion. Summary of results showed that between high SUV and low SUV groups, no statistically significant effect was found (95% CI 0.63–4.52; P = 0.08). This lack of significance could be explained by insufficient study inclusion for the present analyses, which did not allow a definite conclusion in this aspect. In future studies, we should collect more similar type of studies for more comprehensive research.

There exist a number of limitations in our study. First, our meta-analysis was restricted to articles published only in English. Secondly, the methodology used did not prevent all of the potential biases (e.g. Additional file 1: Figure S1; Additional file 2: Figure S2; Additional file 3: Figure S3; Additional file 4: Figure S4), which was partially due to the fact that studies with nonstatistically

---

**Fig. 3** Forest plot of 7 included studies in ΔSUV for OS. Pooled effect (HR) and heterogeneity test of a metabolic responding on OS in patients with liver metastases (OS: overall survival)

**Fig. 4** Forest plot of 6 included studies in pretreatment SUV for OS. Pooled HR compared low SUV group with high SUV group in patients with liver metastases.
significant results were less often published. Third, the clinical heterogeneity may also account for the test results, since among included studies patients received different therapies (e.g., various chemotherapy schemes with or without bevacizumab and the types of surgery or surgical techniques) that may all influence the outcomes. Last but not least, some of the included studies did not provide sufficient data of time-to-event outcomes for meta-analysis directly. We had to use Engauge Digitizer to extract data from survival curves, which may result in certain inaccuracy. Nevertheless, the validity of the major findings in this study has been supported by more recent clinical studies [38, 39].

Conclusion
In conclusion, the present meta-analysis confirms that the patients before treatment with high SUV $^{18}$FDG PET/CT images and patients with metabolically nonresponding $^{18}$FDG PET/CT images may be considered at high risk of death or treatment failure. Therefore, the SUV of $^{18}$FDG PET/CT is a useful tool to help predict survival outcomes in colorectal cancer patients with liver metastases.

Additional files

Additional file 1: Figure S1. Funnel graph for the assessment of potential publication bias in studies about ΔSUV for EFS. (DOCX 17 kb)
Additional file 2: Figure S2. Funnel graph for the assessment of potential publication bias in studies about ΔSUV for OS. (DOCX 17 kb)
Additional file 3: Figure S3. Funnel graph for the assessment of potential publication bias in studies about pretreameent SUV for OS. (DOCX 17 kb)
Additional file 4: Figure S4. Funnel graph for the assessment of potential publication bias in studies about posttreament SUV for OS. (DOCX 23 kb)

Abbreviations
$^{18}$FDG PET/CT: $^{18}$fluorodeoxyglucose positron emission tomography CT; $^{90}$Y: Yttrium-90; ΔSUV: Follow-up SUV values; CI: Confidence intervals; DFS: Disease-free survival; EFS: Event-free survival; HR: Hazard ratio; OS: Overall survival; PFS: Progression-free survival; RFS: Relapse-free survival; SIRT: Selective internal radiation therapy; SUV: Standardized uptake value.

Competing interests
The authors had no conflict of interest to declare in relation to this article.

Authors’ contributions
Authors QX(YL)/YCHN conceived and designed the study. Authors JL, SL, LJ, YBF, YSHJ searched relevant article and extracted the data which was rechecked by YWL to resolve any disagreement between the two data retrievers. CHW performed statistical analysis. QX and TY analyzed the result and QX wrote the paper. YCHN revised the final manuscript critically for important intellectual content. All the authors read and approved the final manuscript.

Acknowledgements
This study was partially financed by “973” Project (No. 2012CB932604), New Drug Discovery Project (No. 2011ZX09506-001-005), Shanghai First-class Discipline (Medical technology), National Natural Science Foundation of China (No. 81372195, 81471685 & 81471687), Founding of Shanghai Municipal Health Bureau (20124170); China Scholarship Council (201204490179) and the Education and Training Department of the Flemish Government (1F2BBG/JDW/2013-2014/13-BLT-CHI-02). Yicheng Ni is currently a Bayer Lecture Chair holder.

Author details
1Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160, Pu Jian road, Shanghai 200127, China. 2Department of Health Statistics, Second Military Medical University, No. 800, Xiang Yin road, Shanghai 200433, China. 3Department of Imaging and Pathology, University Hospitals, KU Leuven, Herestraat 49, Leuven 3000, Belgium.

Received: 14 July 2015 Accepted: 15 November 2015 Published online: 20 November 2015

References
1. Nordlinger B, Sorbye H, Gilmerous B, Poston GJ, Schlag PM, Rouppe V, et al. PET/CT: a new paradigm for imaging. J Clin Oncol. 2001;19:3058–62.
2. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, et al. FDG PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13 Suppl 2:8–13.
3. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–65.
4. Kostakoglu L, Coleman M, Leonard JP, Kuij I, Zee H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43:1018–27.
5. Ott K, Weber WA, Lortick F, Becker K, Buch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–8.
6. Saini S. Radiologic measurement of tumor size in clinical trials: past, present, and future. Am J Roentgenol. 2001;176:333–4.
7. Van den Abbeele AD. The lessons of GIST – PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13 Suppl 2:8–13.
F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med. 2012;53:371–7.

11. Lactoria S, Piccillo MC, Caracò N, Nasti G, Akoj L, Aricchiello C, et al. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med. 2013;54:2062–9.

12. Zhao Q, Feng Y, Xiao X, Qie M. Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography or PET-Computed Tomography in Cervical Cancer. Int J Gynecol Cancer. 2013;23:1184–90.

13. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buivat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is prognostic for survival in Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2008;3:56–12.

14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.

15. Wang Y, Zeng T. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2013;19:391.

16. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Brit Med J. 2003;327:557–60.

17. Small RM, Lubesky N, Shmueli E, Figer A, Adenka D, Nakake R, et al. Response to chemotherapy predicts survival following resection of hepatic colorectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol. 2009;99:93–8.

18. De Bruyne S, Van Damme N, Smeets P, Ferdinandae L, Ceelen W, Mertens J, et al. Value of DCE-MR and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab in colorectal liver metastases. Br J Cancer. 2012;106:1926–33.

19. Mertens J, De Bruyne S, Van Damme N, Smeets P, Ceelen W, Troisi R, et al. Standardized added metabolic activity (SAMA) IN 18-FDG PET assessment of treatment response in colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2013;40:1214–22.

20. Lee HS, Kim HO, Hong YS, Kim TW, Kim JC, Yu CS, et al. Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery. J Nucl Med. 2014;55:582–8.

21. Riedl CC, Akhurst T, Larson S, Stanzaile SF, Tuurto S, Bhagava A, et al. 18 F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771–5.

22. Hendiliz A, Golfinopoulos V, Garcia C, Covas A, Eomonte P, Ameyo L, et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2012;23:1687–93.

23. Zerizer I, AH AHASHE A, Towey D, Tait P, Ariff B, Wasan H, et al. The role of early 18 F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumor density criteria. Eur J Nucl Med Mol Imaging. 2012;39:1391–9.

24. Fendler WP, Philippe Tiega DB, Ilhan H, Paprotka PM, Heinemann V, Jakobs TF, et al. Validation of Several SUV-Based Parameters Derived from 18-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer. J Nucl Med. 2013;54:1202–8.

25. Muralidharan V, Kwok M, Lee ST, Lau L, Scott AM, Christophi C, et al. Prognostic Ability of 18 F-FDG PET/CT in the Assessment of Colorectal Liver Metastases. J Nucl Med. 2012;53:1345–51.

30. Zalom M, Yu R, Friedman M, Bresee C, Waxman A. FDG PET/CT as a Prognostic Test After 90Y Radioembolization in Patients With Metastatic Hepatic Disease. Clin Nucl Med. 2012;37:862–5.

31. Bos R, van der Hoeven JJ, van der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.

32. Brücher BL, Weber W, Bauer M, Fink U, Avril N, Steen HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300–9.

33. Findlay M, Young H, Cunningham D, Isonon A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700–8.

34. Lau LF, Williams DS, Lee ST, Scott AM, Christophi C, Muralidharan V. Metabolic response to neoadjuvant chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. Ann Surg Oncol. 2014;21:4242–8.

35. de Geus-Oei LF, Wiering B, Krabbe PF, Ruers TJ, Punt CJ, Oyen WJ. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol. 2006;17:1650–5.

36. Hijikish Ueda Y, Ariaka Y, Sakuma T, Nambo Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:3945.

37. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on 18fluoro-2-deoxy-glucose positron emission tomography scan in non-small cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201–6.

38. Tarn HH, Cook GJ, Chau I, Drake B, Zerizer I, Duy Y, et al. The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis. Clin Nucl Med. 2015;40:259–64.

39. Sabat A, Meyer C, Aouf A, Sabat A, Ghamari S, Pieper CC, et al. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Mol Imaging. 2015;42:370–7.